In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.48.
Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, MoonLake Immunotherapeutics, and Regulus. According to TipRanks, Selvaraju has an average return of -8.4% and a 32.48% success rate on recommended stocks.
Currently, the analyst consensus on Spero Therapeutics is a Moderate Buy with an average price target of $6.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Spero Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.07 million and a GAAP net loss of $13.27 million. In comparison, last year the company earned a revenue of $2.07 million and had a GAAP net loss of $32.83 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Read More on SPRO:
